Expanding the Encyclopedia of **DNA Elements** (ENCODE) in the Human and Mouse (UM1)



Leading the search for tomorrow's cures

# ENCODE in the Human and Mouse (UM1)- Mapping Centers

FOA	Deadlines	Funding Level			
<b>RFA-HG-16-002</b>	LOI: Feb 21, 2016	Budget: \$2-2.5 Million/YR;4 YRS			
	App: Mar 21, 2016	Total: \$15.5-20M for 6-8 awards			

# NHGRI's highest priorities:

- Maps of transcribed regions
- Maps of chromatin accessibility
- Maps of histone marks
- Maps of other relevant chromatin proteins
- Maps of sites of DNA methylation
- Maps of long range chromatin interactions

"These centers should employ high-throughput, genome-wide and cost-effective experimental pipelines for a range of genomic assays capable of generating high quality data to map biochemical activities, exhibited by the <u>human</u> and <u>mouse (10%)</u> genomes, that are associated with functional elements."

"to encourage highly focused research projects and streamline data management, projects are sought that propose the use of <u>only one biochemical assay</u> (e.g., ChIPseq, RNAseq, and variations thereof). An additional 1-2 assay(s) per application may be considered if they are strongly justified in terms of how centralizing data production within one group,"

"new or improved assays may be applied across a relatively small set of <u>common samples previously used within ENCODE</u> (for which significant amounts of ENCODE data already exist)"

# Scientific questions (theme):

Structure codes for chromatin topology and their functions in human genomes

# Genetic code:

- Gene codes (gene-centric views) protein coding sequences, codon usage TSS, exon, intron, splicing site, etc
- 2. Are there structure codes for genome topology? non-coding, distal, regulatory elements insulator, enhancer, repressor, etc

CFCT binding motif is a major kind of S-codes

- abundant, genome-wide, chromatin interactions
- Hi-C data showed CTCF associated w/ TAD (80%)
- ChIA-PET showed CTCF define chromatin topology

# CTCF binding/looping defines chromatin topology



Size distribution of loop and domain 1.00 Indiv. CTCF loop 0.75 In situ Hi-C loop 0.50 Hi-C TAD 0.25

1Mb

Genomic span

10Mb

100Mb

100kb

Cumulative density

0.00

10kb

CCD = TAD

CTCF loops define detailed domain and sub-domain structures

#### CCD

### 2D mapping data





# Structure code variation and what affects it ?

# Epigenetic effects,

# Genetic effects,

In same genotype (individual) Diff. epigenotypes Diff. cell types

dividual) In same epigenotype (cell type) Diff. genotypes Diff. individuals

# Cell type-specific CCD structure



# Cell type-specific CCD structure



- 3D genome architecture is dynamic during development and differentiation
- Chromatin topology could be a regulatory mechanism for cell-type specificity

# Genetic (SNP) validation of CTCF binding and looping

#### chr6:31426075-31930740 (504 kb)



# GM12878 and HeLa CTCF binding comparison

~20% CTCF bindings are exclusive to one cell type, two possible causes:

- 1.Genetic variation
- 2.Cell-type specificity





Example showing variation of CTCF binding/looping between GM12878 and HeLa

chr1:225296376-226608645 chr1:225920559-226271635 H3F3A RP4-559A3.6 Gencor SDE2 RP4-559A3.7 RP11-145A3.1 SRP EPHX1 Genco DNAH1 PARI H3F3A LIN9 LEFTY1 SDE2 RP4-559A3.7 H3F3/ EPHX1 TMEM63A PYCR2 SRPS SRP9 RP11-145A3.2 LIN9 PARI DNAH1 ENAH H SRP9 TMEM63A H3F3A SDE2 CTC  $\langle \rangle \langle$ 1k GM12878 CTCF v 100 GM12878 CTCF \ 100 32 GM12878 U GM12878 CTCF F GM12878 CTCF p -250 -250 -500 -500 -750 -750 100 100 Ц Ц GM12878 PA+ GM12878 PA+ 50 50 MUNIT -50 -100 316 cohe HeLa CTCF cohe 100 НеЦа HeLa CTCF μ HeLa CTCF peak: HeLa CTCF peak -250 -500 -500 -750 x 100 -750 \$ 11 /0 RN. 100 Hela-S3 P ela-S3 PA+ -100

## Chromatin topology structure variation in diff. cell types



## Chromatin topology structure variation in diff. cell types



B6 Hepatocyte specific CTCF binding and looping surrounding hepatocyte specific genes

## Chromatin topology structure variation in diff. genotypes

-100

-150

e Do

Do Do Do Do

€

UCSC Known Ge

F121 CTCF total

F121 CTCF total

F121 CTCF pater

pater

F121 CTCF

F121 CTCF mate

× ‡

F121 CTC



Mouse ES cells of CAST x 129S



binding/looping. Genetic variant affects "on/off" binding/looping.

Genetic variant affects "weak/strong" binding/looping.





Total capacity of structure codes in human genome?

Possible CTCF motifs in a given genome, ~15 millions (by scan the genome for motifs)



Average CTCF peaks/genome, n=40-50K Total unique CTCF peaks, n=127,983



CTCF binding peak shared in different cell lines

Our strategy to study structure codes of chromatin topology

# Vertical approach (epigenetic):

Same individual, many different cell types

Horizontal approach (genetic):

Same cell type, many different individuals

# Comprehensive Mapping and Elucidating the Structure Codes in Human and Mouse Genomes

Aim 1. Chromatin topology and transcription regulation in ENCODE cells (tie 1 & 2+ cells,  $\approx$  20-30 cell lines)

Aim 2. Mapping structure code in human hematopoietic cells (vertical epigenetic approach, many blood cells from same individuals)

**Aim 3.** Mapping structure code in 1000 human population (horizontal genetic approach, one cell type, 2500 individuals)

Aim 4. Mapping structure code in mouse models (vertical & horizontal approach, 8 founder lines, 200s DO hybrids)

Aim 5. Mapping structure code in human disease populations (100s lupus patient-derived b-cells, 100s T1D patient primary T-cells)

# **Experimental approaches**

# Multiplex ChIA-PET, 10s-100s (8-16 format)

# CTCF, RNAPII, cell-specific TFs, RNA-Seq

Multiplex ChIP-Seq, 100s-1000s (96 format)

CTCF, RNA-Seq

# Preliminary assessment of the 1000 genomes

#### 1000Genomes SNP at CTCF motif



#### CTCF motif prohibits SNP in human genome

CTCF motifs	None SNPs	With CTCF-motif SNPs	Chi-Square Test	
CTCF motifs	12058	8708	n < 0.00001	
Random	10317	10449	ρ < 0.00001	
Gene coding regior	ıs ?	?		



#### chr17:43914683-44373209



CTCF_motif SNP	Location	Functional_SNP	Functional_SNP Types	D-prime	LOD	r-square	SNP function
rs569012614	CTCFboundary	rs11012	GWAS	0.882	15.12	0.654	
rs569012614	CTCFboundary	rs17631303	GWAS	0.919	16.19	0.685	
rs569012614	CTCFboundary	rs2942168	GWAS	1	26.25	0.909	Parkinson disease
rs569012614	CTCFboundary	rs393152	OMIM_GWAS	1	26.25	0.909	Parkinson disease
rs569012614	CTCFboundary	rs12185268	GWAS	1	26.25	0.909	Parkinson disease
rs569012614	CTCFboundary	rs12373124	GWAS	1	26.25	0.909	
rs569012614	CTCFboundary	rs17690703	GWAS	1	20.18	0.722	
rs569012614	CTCFboundary	rs1864325	GWAS	1	26.25	0.909	
rs569012614	CTCFboundary	rs17649553	GWAS	1	25.17	0.882	Parkinson disease
rs569012614	CTCFboundary	rs1800547	OMIM	1	26.25	0.909	Parkinson disease
rs569012614	CTCFboundary	rs1981997	GWAS	1	26.25	0.909	
rs569012614	CTCFboundary	rs63750417	clinVar	1	26.25	0.909	
rs569012614	CTCFboundary	rs62063786	clinVar	1	26.25	0.909	
rs569012614	CTCFboundary	rs62063787	clinVar	1	26.25	0.909	
rs569012614	CTCFboundary	rs10445337	clinVar	1	26.25	0.909	
rs569012614	CTCFboundary	rs1052551	clinVar	1	26.25	0.909	
rs569012614	CTCFboundary	rs62063845	clinVar	1	26.25	0.909	
rs569012614	CTCFboundary	rs1052553	clinVar	1	26.25	0.909	
rs569012614	CTCFboundary	rs17652121	clinVar	1	26.25	0.909	
rs569012614	CTCFboundary	rs8070723	GWAS	1	26.25	0.909	
rs569012614	CTCFboundary	rs9303525	GWAS	1	25.17	0.882	
rs569012614	CTCFboundary	rs17577094	GWAS	1	26.25	0.909	Parkinson disease
rs569012614	CTCFboundary	rs183211	GWAS	1	22.76	0.807	
rs569012614	CTCFboundary	rs199533	GWAS	1	28.89	0.968	Parkinson disease
rs569012614	CTCFboundary	rs199515	GWAS	0.967	26.57	0.936	Parkinson disease
rs569012614	CTCFboundary	rs415430	GWAS	0.966	24.85	0.903	Parkinson disease

chr17:43914683-44373209



# Project Schedule (Proposed)

Grant Submission Timeline	Due Date	Days to Complete	<u>e Status Comment</u>
Submit LOI	2/21/2016	5 25	Yijun/Jo Anne
Final Draft Review	3/14/2016	5 47	Red Team (JAX Peers)
Submit	3/17/2016	5 50	OSP
Narrative Preparation Timeline	Due Date	Days to Complete	<u>e Status Comment</u>
Team Meeting (BH)	1/28/2016	5 I	
NIH Meeting (Elise Feingold, Mike Pazen)	2/5/2016	5 9	Jo Anne to organize
Budget	2/11/2016	5 15	Yijun, Team, Jon Maslow
First Complete Draft - ALL Sections	SEE BELOW		
Overall Goals: 6 pages	2/4/2016	8	Yijun
Experimental Assay Section: 12 pages	2/18/2016	5 22	Yijun, Greg, Laura (mouse)
Selection of Biological Samples Section: 6 pages	2/18/2016	5 22	Yijun, JB/VP, Greg/Laura
Data Management Plan: 6 pages	2/18/2016	5 22	Yijun, Greg, Mark
Project Management Plan: 6 pages	2/18/2016	5 22	Yijun
1000 genomes			Yijun
Mouse DO/CC			Greg and Laura
Disease- Lupus			JB and VP
Disease- TID			Derya, Dave
Functional validation			Laura, Albert, Haoyi
Second Draft- ALL SECTIONS- Red team review	2/25/2016	5 29	
and REVIEW FOR INTEGRATION	3/7/2016	<b>4</b> 0	
Final Drafts- ALL SECTIONS	3/14/2016	6 47	
Final Production	Due Date	Days to Complete	<u>Status Comment</u>
Forms Package	3/17/2016	5 50	

#### GM12878 SNP in CTCF motifs



# Article

# CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription

Zhonghui Tang,<sup>1,12</sup> Os Przemyslaw Szalaj,<sup>4,5,6</sup> Emaly Piecuch,<sup>1,3</sup> Ping Xiaoan Ruan,<sup>1</sup> Chia-Lii and Yijun Ruan<sup>1,2,3,\*</sup> <sup>1</sup>The Jackson Laboratory ( <sup>2</sup>National Key Laboratory ( Hubei 430070, China

